Drug Detail:Ixazomib citrate (monograph) (Ninlaro)
Drug Class:
Ixazomib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of ixazomib during breastfeeding. Because its half-life is about 9.5 days, it is likely to accumulate in the infant. It is also given in combination with leflunomide and dexamethasone, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during ixazomib therapy and for 90 days after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Ixazomib
CAS Registry Number
1072833-77-2
Drug Class
-
Breast Feeding
-
Lactation
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Protein Kinase Inhibitors
-
Signal Transduction Inhibitors
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification
